Full Press Release Details
Jaguar Health & SynWorld Technologies Mutually Agree to Terminate
License and Commercialization Agreement for Canalevia for Treatment of Diarrhea in Dogs in China Given Jaguar's 2023 Focus on Human
Tao Wang, SynWorld's General Manager and a long-term shareholder
of restricted Jaguar stock, fully aligned on termination decision
SAN FRANCISCO, CA / ACCESSWIRE / February
1, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") and SynWorld Technologies Corporation
(SynWorld) today announced that the two companies have mutually agreed to terminate the exclusive license and services agreement (the
"Canalevia Agreement") executed in June 2022 for the treatment of diarrhea in dogs in the China market with Jaguar's Canalevia
(crofelemer delayed-release tablets) prescription drug product effective January 31, 2023.
"Given Jaguar's sharp strategic
focus in 2023 on human drug development - specifically on our Phase 3 pivotal OnTarget trial
of crofelemer for our core follow-on indication of prophylaxis of cancer therapy-related diarrhea (CTD) and our crofelemer development
efforts for the rare disease indications of short bowel syndrome (SBS) and congenital diarrheal disorders (CDD) - we and SynWorld have
agreed that it makes sense to terminate the Canalevia Agreement at this time," said Lisa Conte, Jaguar's founder, president, and
CEO. "Jaguar is concentrating on two late-stage clinical events in the next approximately 6 months that we expect to be transformational
in terms of value creation and recognition for the Company. We expect enrollment in the OnTarget trial to complete in the second quarter
of 2023. Our second prioritized clinical program centers around the investigator-initiated proof-of-concept trial of crofelemer for SBS
and CDD with intestinal failure."
"Jaguar and SynWorld are fully aligned on our mutual decision
to terminate the Canalevia Agreement, because Jaguar is understandably wholly focused on its core drug development milestones on the human
front at this time," said Tao Wang, SynWorld's General Manager and a long-term shareholder of restricted Jaguar stock. "Jaguar
and SynWorld may jointly revisit possible opportunities in the future with regard to the potential consumer demand in China for Canalevia,
keeping in consideration the impact that the geopolitical climate could have on the operating environment in this regulated animal health
On the effective date of termination of the Canalevia Agreement,
all licenses granted to SynWorld by Jaguar under the Canalevia Agreement were revoked and the rights granted thereunder reverted back
About SynWorld Technologies Corporation
SynWorld Technologies Corporation employs cutting edge technology
to facilitate opportunities for companies in the U.S. to reach international markets, specifically, China. This is particularly important
for publicly traded U.S. based companies who need distribution and Chinese compliance-related logistic partnerships.
About Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics &
Jaguar Animal Health
Jaguar Health, Inc. is a commercial stage
pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people
and animals with GI distress, including chronic, debilitating diarrhea. Jaguar Health'swholly owned subsidiary, Napo Pharmaceuticals,
Inc., focuses on developing and commercializing proprietary plant-based human pharmaceuticals from plants harvested responsibly from
rainforest areas. Our crofelemer drug product candidate is the subject of the OnTarget study,
an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. Jaguar Health
is the majority shareholder of Napo Therapeutics S.p.A. (f/k/a Napo EU S.p.A.), an Italian corporation established by Jaguar Health in
Milan, Italy in 2021 that focuses on expanding crofelemer access in Europe. Jaguar Animal Health is a tradename of Jaguar Health.
information about Jaguar Health, please visit https://jaguar.health. For more information
about Napo Pharmaceuticals, visit www.napopharma.com. For
more information about Napo Therapeutics, visit napotherapeutics.com.
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements." These include statements regarding Jaguar's expectation that two late-stage clinical events
in the next approximately 6 months may be transformational in terms of value creation and recognition for the Company, Jaguar's
expectation that enrollment in theOnTarget trial will complete in the second quarter of 2023, and the expectation that Jaguar and
SynWorld may jointly revisit possible opportunities in the future with regard to the potential consumer demand in China for
Canalevia. In some cases, you can identify forward-looking statements by terms such as "may," "will,"
"should," "expect," "plan," "aim," "anticipate," "could,"
"intend," "target," "project," "contemplate," "believe," "estimate,"
"predict," "potential" or "continue" or the negative of these terms or other similar expressions. The
forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its
current expectations and projections about future events. These forward-looking statements speak only as of the date of this release
and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of
which are beyond Jaguar's control. Some of the factors that could affect our actual results are included in the periodic reports on
Form 10-K and Form 10-Q that we file with the Securities and Exchange Commission. Except as required by applicable law, Jaguar does
not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information,
future events, changed circumstances or otherwise.
SOURCE: Jaguar Health, Inc.
and-Commercialization-Agreement-for-Canalevia-for-Treatment-of-Diarrhea-in-Dogs-in-China-Given-Jaguars-2023-Focus- on-Human-Drug-Development